Evidence map›Paper›PMID 41473975›Full record

ReviewChinese medical journal2026

Biological significance, molecular mechanisms and clinical potential of EI24 in cancer.

Wanli Yang, Chenyang Wang, Xinhui Zhao, Daiming Fan, Liu Hong

Abstract readReview
In one paragraph

Review in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wanli YangDepartment of Digestive Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Chenyang WangDepartment of Digestive Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Xinhui ZhaoDepartment of Thyroid and Breast Surgery, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, Shaanxi 710018, China.
Daiming FanState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Liu HongDepartment of Digestive Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractRecent studies have revealed aberrant expression patterns of the autophagy-associated transmembrane protein etoposide-induced 2.4 (EI24) in diverse cancer types, prompting investigations into its potential as a biomarker for cancer. These findings underscore the multifaceted roles of EI24 in regulating critical processes such as tumor metastasis, proliferation, angiogenesis, drug resistance, tumor microenvironment, and autophagy, both indirectly and directly. Such insights also provide a foundation for further elucidating the underlying mechanisms of EI24's involvement in tumorigenesis, thereby facilitating the development of novel therapeutic approaches. In this review, we present the latest advancements in EI24 research within the realm of tumor biology. We delve into the intricate molecular mechanisms governing EI24's functions across various tumor types and its diagnostic and prognostic significance. In addition, we analyze emerging therapeutic strategies targeting EI24 in tumors, offering insights into its potential as a future therapeutic target. A comprehensive understanding of EI24's role in tumor biology is crucial for devising innovative therapeutic approaches tailored to the diverse complexities of various cancer types. By integrating mechanistic insight with translational potential, EI24 represents a key node linking biological understanding to next-generation diagnostic and therapeutic innovations.

Indexed as

NeoplasmsAnimalsAutophagyHumansTumor MicroenvironmentDiagnostic biomarkerEtoposide induced 2.4Pharmacological agentsPrognostic biomarkerTargeted therapy

Identifiers

PMID41473975
PMCPMC12875698

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.